CompletedNCT00111189
Paliperidone palmitate to help prevent schizophrenia symptoms from returning
About this title
A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.
Read the official source — NCT00111189Medication studyAges 18–65Multiple countries
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Little Rock and 54 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateFebruary 2005
- Recruitment status
- Completed
- Enrollment listed in the registry
- 414
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Costa Rica, Mexico, ...
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT00111189
- Official title
Show the full official title
A Randomized Double-blind Placebo-controlled Parallel Group Study Evaluating Paliperidone Palmitate in the Prevention of Recurrence in Patients With Schizophrenia. Placebo Consists of 20% Intralipid (200 mg/mL) Injectable Emulsion.
Get this study by email
Recruitment & locations
CompletedLittle Rock, United States · Cerritos, United States · Santa Ana, United States
53 more locations
- Hialeah, United States
- Chicago, United States
- Granite City, United States
- Lake Charles, United States
- Shreveport, United States
- Flowood, United States
- St Louis, United States
- Clementon, United States
- Cedarhurst, United States
- Cleveland, United States
- Oklahoma City, United States
- Conroe, United States
- DeSoto, United States
- Irving, United States
- San Antonio, United States
- Costa Rica, Costa Rica
- Mexico City, Mexico
- Mérida, Mexico
- Monterrey, Mexico
- Bucharest, Romania
- Cluj-Napoca, Romania
- Iași, Romania
- Sibiu, Romania
- Tg Mures, Romania
- Timișoara, Romania
- Arkhangelsk, Russia
- Moscow, Russia
- Moscow Russia, Russia
- Saint Petersburg, Russia
- Samara, Russia
- Yaroslavl, Russia
- Cape Town, South Africa
- Centurion Gauteng, South Africa
- Florida Johannesburg Gauteng, South Africa
- Johannesburg, South Africa
- Gwangju, South Korea
- Inchun, South Korea
- Pusan, South Korea
- Seoul, South Korea
- Changhua, Taiwan
- Kaohsiung City, Taiwan
- Tainan, Taiwan
- Taoyuan, Taiwan
- Dnipro, Ukraine
- Hlevakha, Ukraine
- Kharkiv, Ukraine
- Kiev, Ukraine
- Kyiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Simferopol, Ukraine
- Vinnitsa, Ukraine
- Russia
Questions about this study
Who is behind this study?
The study sponsor is Johnson & Johnson Pharmaceutical Research & Development, L.L.C., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo and Paliperidone Palmitate.
Who was this study for?
Listed age limits: 18 years to 65 years.
Want to explore more studies?
Explore studiesRelated studies
Paliperidone Palmitate Compared With Oral Antipsychotic Treatment for schizophrenia
18F-Dihydroxyphenylalanine (DOPA) Positron Emission Tomography (PET) Study to Explore Dopamine Synthesis Capacity in the Whole Striatum After 2 Weeks of Treatment With Ralmitaront or Placebo in Participants With Schizophrenia